MannKind Corp (NASDAQ:MNKD)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer.

Results 1 - 20 of 174 : 1 2 3 4 5 6 7 8 9 Next »

Recs

0
Member Avatar pchop12316 (84.18) Submitted: 8/27/2015 7:21:45 AM : Outperform Start Price: $3.73 MNKD Score: +4.06

niche product line that is very oversold

Recs

0
Member Avatar drugtrader (93.25) Submitted: 8/12/2015 12:12:52 PM : Outperform Start Price: $4.21 MNKD Score: -1.91

Decent product (small, simple to use) with a niche use (meal time, precision glucose control)

Surprised they beat q2, bought 1k shares that I can hopefully refrain from trading as I feel 2016 could be a good year

Recs

0
Member Avatar Herbstmd (51.03) Submitted: 7/25/2015 11:41:23 AM : Underperform Start Price: $5.03 MNKD Score: +17.86

Poor product with limited use, inhalable insulin will be replaced by a cheaper tablet soon.

Recs

0
Member Avatar Turtlebale (63.64) Submitted: 7/21/2015 4:16:27 PM : Underperform Start Price: $5.31 MNKD Score: +20.11

Afrezza

Recs

0
Member Avatar NHWeston102 (21.56) Submitted: 7/4/2015 4:42:22 PM : Outperform Start Price: $5.28 MNKD Score: -22.02

Heavily shorted and regarded warily by the medical community, Afrezza is still revolutionary in potential for diabetic insulin delivery. Support from Sanofi marketeers is key here; in Jan 201, Sanofi either doubles or drops its commitment!!

Recs

0
Member Avatar TerryHoodSr (77.37) Submitted: 6/19/2015 11:19:00 AM : Outperform Start Price: $4.41 MNKD Score: -5.94

MNKD BP 4.5 TP 7.4 5YR EPS 25%

Recs

0
Member Avatar Isaacroo (< 20) Submitted: 4/29/2015 1:10:47 PM : Outperform Start Price: $4.65 MNKD Score: -10.22

Afrezza is going to create tons of $$ revenue diabetes is at an all time high, they will hit 10$ again, and it's hopefully bottomed out

Recs

0
Member Avatar TMFTypeoh (83.67) Submitted: 4/27/2015 2:46:44 PM : Outperform Start Price: $4.57 MNKD Score: -8.32

Stock is been brutal for longs, but Afrezza looks promising. The action curve is so fast, it could be a game changer. Or, it could be a total failure. I'm willing to give a thumbs up to the longs at these prices. Multi bagger or a dud.

Recs

1
Member Avatar jmccolley (34.27) Submitted: 2/6/2015 4:07:45 PM : Outperform Start Price: $7.00 MNKD Score: -40.40

Afrezza will be the first inhaled insulin to actually become accepted by patients, doctors and insurance companies.
It is easy to use and the inhaler fits in the palm of your hand.
It is smaller than the inhalers used by asthma patients.
The technosphere device is revolutionary and will change the way many medications are delivered.

Recs

1
Member Avatar nugjuice (< 20) Submitted: 2/3/2015 4:28:43 PM : Outperform Start Price: $6.50 MNKD Score: -36.57

The bear case just doesn't resonate, and a lot of people have written Afrezza off without knowing much about the product. It's been unfairly (but understandably) compared to Exubera, which differs not only in its bulkiness, but also in its efficacy. Exubera was less effective than injected insulin (and much more expensive) which meant the only value-added was being able to inhale instead of inject. Afrezza not only is inhaled (with an inhaler the size of a whistle instead of a bong) but it also has better efficacy and a faster acting profile than traditional injected meds, with competitive pricing. With 30% of the float short, this is a no-brainer with reward positively skewed to the upside

Recs

1
Member Avatar FoundryOnStocks (46.49) Submitted: 1/27/2015 3:21:35 PM : Outperform Start Price: $6.33 MNKD Score: -35.40

$9 price target by February 2016.

Recs

0
Member Avatar missjessiecat (< 20) Submitted: 1/13/2015 12:59:34 PM : Outperform Start Price: $5.61 MNKD Score: -27.17

Although there is still substantial risk in MNKD, I believe the risk will dwindle considerably over the next 12 months and I also believe that the upside potential is enormous! If I'm right about these two predictions, as the risk goes down, the share price will explode. Afrezza sales should be very strong this year and many more opportunities will develop that makes use of their Technosphere technolgy! I just can't believe that the current share price is this low!

Recs

0
Member Avatar JCLscapXperiment (93.78) Submitted: 12/14/2014 6:57:28 PM : Underperform Start Price: $5.14 MNKD Score: +21.82

Jan17 Put $1, $3 Strike

Recs

0
Member Avatar rbitrage (86.44) Submitted: 10/13/2014 9:26:29 PM : Underperform Start Price: $4.71 MNKD Score: +21.94

Not much cash on the books. The company has financial problems and the current market won't allow the company to go back to the market to get more equity.

Recs

0
Member Avatar SegaRob (41.04) Submitted: 10/2/2014 4:03:58 PM : Outperform Start Price: $5.55 MNKD Score: -30.47

There is a huge market for Afrezza (inhaled insulin) and the technosphere technology that allows medications that previously required injections to be taken via an inhaler. Revenues from Afrezza are likely to be north of $1b in 2015 and further growth after that especially since there continues to be a rise in diabetic patients. Stock is currently trading at market cap close to $2b. I think the stock is worth at least $10 making current price of $5.55 a big bargain.

Recs

0
Member Avatar beppaun (67.78) Submitted: 10/2/2014 3:49:14 PM : Outperform Start Price: $5.56 MNKD Score: -31.15

One of the highest short interest ratio for a company that could be near profitability after agreement with Sanofi

Recs

0
Member Avatar jbwheels69 (71.24) Submitted: 10/1/2014 1:32:26 PM : Outperform Start Price: $5.55 MNKD Score: -30.96

Great partner in SNY leader in the diabetes space. Great potential to be a block buster.

Recs

8
Member Avatar zzlangerhans (99.79) Submitted: 9/20/2014 2:52:27 AM : Outperform Start Price: $7.04 MNKD Score: -43.17

It's a little sad that the five year price chart on YahooFinance doesn't take me back all the way to when I started covering Mannkind. I always thought I'd be a stock market billionaire before I got to this point. Perhaps I'm not because I never put my money where my mouth was on Mannkind, yet in the end I was right each of the dozen or so times that I pitched it. Mannkind is the epitome of a momentum stock. Both the upward and downward pressures on the stock are extreme, which can easily lead to a deceptively placid lull in movement. Nevertheless, when one side gains the upper hand the share price always overshoots dramatically. Almost no one ever buys Mannkind near the lows or shorts it near the top. The profits come to those with the courage of their convictions and the reserves to double down.

These days, the tide is running out and it isn't done. I know it's not done because I'm thinking about buying some and I haven't bought yet. It's a virtual certainty that as soon as I finally pull the trigger the stock will give up another 20%. The approval is done and the partnership is done, and now Mannkind must prove there's a market. As always, once the catalyst is past the opposing camp is in control. Last catalyst positive = momentum negative. The skeptics are confident that Afrezza won't capture any market share, and if it does it won't be profitable, and if it is it won't be profitable enough to justify the market cap. They may be right. but at some point in the near future something will happen to re-energize the Mannkinder and this stock will come roaring back. The only question is if the stock will dip back under 3 before that happens. That's why if you play this stock you always start small. If you happen to time the bottom and win small, at least you won on Mannkind. That's more than a lot of pros can say. If you have the reserves to double down when your small bet is down 20-30%, all the better.

Of course, who knows whether Mannkind will enter a Dendreon-like swirl of escalating losses and debt culminating in an agonizing bankruptcy? If that wasn't a possibility, the stock wouldn't be declining. In the end, though, trading stocks involves risk and trading biopharmas is especially risky. Ultimately, I have to trust the track record I've built on the stock over seven years rather than whichever talking head is talking out of whichever side of his mouth on CNBC or Seeking Alpha. Mannkind will be back.

Recs

0
Member Avatar AMax101 (32.18) Submitted: 7/24/2014 11:33:13 AM : Underperform Start Price: $9.46 MNKD Score: +57.46

Afrezza sales will be a disappointment. Labeling issues will restrict doctors from actually prescribing the drug. Predicting another Exubera bust.

Recs

0
Member Avatar RCSingh (< 20) Submitted: 7/23/2014 11:56:38 PM : Outperform Start Price: $9.50 MNKD Score: -57.73

Mannkind is sitting on an up and coming pop in the near-term future. Yes the analysts who say that the upside of increased earnings (slash the very existence of earnings) is already factored into the price of the stock are correct. But the old adage of "buy the rumor, sell the news" still works as well today as it used to. Once the rumors about which distributor(s) they're talking to come to the surface, this one is a great candidate for deep ITM leaps...takes the worrying out of waiting for those rumors to come to light.

Featured Broker Partners


Advertisement